Effects of oral adsorbent AST-120 concurrent with a low-protein diet on the progression of chronic renal failure.
This study was designed to examine the effects of oral adsorbent AST-120 on the progression of CRF in patients on strict LPD. Thirteen patients with CRF (serum creatinine: 1.8-8.2 mg/dl) that had been kept on LPD (0.4-0.7 g/kg/day) were enrolled in this study. After LPD alone for 5-24 months, AST-120 (3-6 g/day) was administered concurrently with the LPD for an additional 5-13 months. In 9 of the 13 patients, the slopes of reciprocal creatinine (Cr) vs. time plot linearly declined before AST-120 treatment. After treatment, the slopes of these patients lessened from -0.01 +/- 0.001 to -0.003 +/- 0.001 dl/mg/month (p < 0.01). Because reciprocal Cr did not decline linearly with time before AST-120 treatment in the remaining 4 patients, the slopes of reciprocal Cr could not be compared before and after treatment with AST-120. Seven of the 9 patients had sufficient creatinine clearance (Ccr) data after treatment with AST-120. The decline of Ccr decreased from -0.59 +/- 0.13 to -0.12 +/- 0.12 ml/min/month in these patients. This study has clearly demonstrated that AST-120 compounds the effects of well-controlled LPD on retarding the progression of CRF. AST-120 may remove some uremic metabolite(s) which promote the progression of CRF.
Owada
A
A
Department of Internal Medicine, Toride Kyodo General Hospital, Ibaraki, Japan.
Shiigai
T
T
D000284:Administration, Oral; D000327:Adsorption; D002244:Carbon / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003401:Creatine / Q000378:metabolism*; D003404:Creatinine / Q000097:blood; D018753:Diet, Protein-Restricted; D018450:Disease Progression; D006801:Humans; D007668:Kidney / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000503:physiopathology* / Q000628:therapy; D008863:Microspheres; D010087:Oxides / Q000008:administration & dosage*
D010087:Oxides; D002244:Carbon; C040896:AST 120; D003404:Creatinine; D003401:Creatine